Acelyrin’s chief legal officer Murugan Amar sells $10,737 in stock

Murugan Amar, the Chief Legal Officer at Acelyrin, Inc. (NASDAQ:SLRN), sold 3,913 shares of common stock on March 17, 2025. The shares were sold at a weighted average price of approximately $2.744, totaling $10,737. Following this transaction, Amar holds 121,587 shares in the company. The sale comes as SLRN trades near $2.78, down roughly 47% over the past six months, though the company maintains a strong balance sheet with more cash than debt and a healthy current ratio of 7.15.

The sale was executed to satisfy tax obligations related to the vesting of certain restricted stock units, as per the company’s policy. This transaction was not a discretionary sale by Amar. The shares were sold in multiple transactions with prices ranging between $2.71 and $2.76. With earnings scheduled for March 27, investors can access comprehensive insider trading analysis and additional key metrics through InvestingPro’s detailed research reports.

In other recent news, Acelyrin Inc. has announced the termination of its License and Collaboration Agreement with Affibody AB, marking a significant shift in its business strategy. This decision will relieve Acelyrin of any financial or other obligations related to the agreement once the termination is complete. Additionally, Acelyrin has confirmed receiving an unsolicited buyout proposal from Concentra Biosciences, which offers $3.00 per share plus a contingent value right. This proposal comes amidst Acelyrin’s ongoing merger agreement with Alumis Inc., expected to finalize in the second quarter of 2025.

In response to Tang Capital Partners (WA:CPAP)’ acquisition of 8.8% of its shares, Acelyrin has adopted a stockholder rights plan to protect against further acquisitions. Meanwhile, analysts from Citi and H.C. Wainwright have adjusted their price targets for Acelyrin, both maintaining a Neutral rating. Citi has lowered its target to $3.00, citing uncertainty in Acelyrin’s Phase 3 program for lonigutamab, while H.C. Wainwright has reduced its target to $6.00, reflecting recent findings from the Phase 1/2 study. Acelyrin’s board continues to focus on maximizing shareholder value as these developments unfold.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.